Why are top athletes using diabetes tech in pursuit of medals?
June 10 (Reuters) -Some Olympic athletes are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels.
The market for continuous glucose monitors (CGMs), developed to help diabetes patients fine-tune their insulin shots, is already worth billions of dollars per year.
Manufacturers are eyeing further growth in the sport and wellness sector, where top athletes could be trend-setters.
WHAT ARE CGMs?
CGMs are coin-size skin patches with a wireless link to a smartphone. With the help of an applicator needle, a tiny sensor filament is pierced into the upper arm to measure glucose between cells just underneath the skin. The adhesive patch holds the sensor in place for up to two weeks.
Current models have become smaller and more precise and no longer need separate receiver hardware.
HOW ARE ATHLETES USING CGMs?
Some top athletes and their support staff use CGMs to assess calorie intake and workout intensity. The benefit during races lasting less than about three hours is seen as limited.
Retired Australian swimmer and Olympic gold medallist Chelsea Hodges says CGMs helped her remedy bouts of extreme exhaustion during longer training sessions. Minute-by-minute monitoring showed she was prone to sagging blood glucose levels.
Dutch marathoner Abdi Nageeye won silver at the Tokyo Olympics. Seeking an "effortless run", Nageeye is using CGMs to improve sleeping and eating patterns so that he expends a minimum of energy during training.
Swedish steeplechaser Emil Blomberg, another Tokyo Olympian seeking to qualify for Paris, said he used CGMs to prevent overtraining. The devices also helped him work out that he needs to eat more during longer training sessions.
IS USE OF CGMs FAIR?
Cycling's world governing body UCI in 2021 banned the non-medical use of CGMs during races "to ensure the respect of individual qualities, the spirit of competition, and fairness" but other major sports have not followed suit.
Some athletes say the cost of CGMs - Abbott's ABT.N Lingo device, available in Britain, costs 120-150 pounds ($152-190) per month - can be prohibitive without a sponsorship deal.
Sports nutrition researchers say benefits have so far been anecdotal, with no clear evidence CGMs give a competitive edge.
WHAT IS THE SCIENCE BEHIND CGMs IN SPORTS?
Understanding how glucose tracking can inform an athlete's calorie intake and training schedule is still in its infancy.
Using up more energy in training than calories available from food, for example, can over time compromise bone strength, the immune system and fertility. However, it has not yet been fully established how CGMs can help avoid that.
Among some surprise research findings, elite marathoners have remarkably high blood glucose levels during races, likely boosted by stress hormones. Many endurance athletes have extremely low glucose levels during pre-dawn sleep but it's not clear whether that is detrimental.
Researchers told Reuters that most of their CGM advisory work for athletes without diabetes is for now based on anecdotal observations rather than validated findings.
WHAT CGMs ARE AVAILABLE FOR NON-DIABETICS?
Companies like Levels, Nutrisense and Signos offer apps and programmes for non-diabetics to use in combination with diabetes devices made by Dexcom DXCM.O or Abbott. The programme providers are not directly associated with the manufacturers.
Abbott in 2020 launched the CGM Libre Sense Glucose Sport Biosensor for athletes without diabetes in a number of European countries. It was exclusively available via a collaboration with app developer Supersapiens, but that company shut in February.
CEO Phil Southerland told Sports Business Journal that a capital increase had fallen flat and he would seek to relaunch with a U.S. focus. He did not respond to requests for comment.
Abbott in January launched a CGM with a coaching app in Britain, branded Lingo, for "overall health and wellbeing". The group is next looking to launch in the U.S..
($1 = 0.7863 pounds)
Reporting by Ludwig Burger; Editing by Catherine Evans
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
